Febrile Neutropenia: FDA Approves Pegfilgrastim Biosimilar

The FDA has now approved pegfilgrastim-apgf (NyvepriaTM, Pfizer), a biosimilar of pegfilgrastim (Neulasta®, Amgen), for the prevention of febrile neutropenia in patients receiving myelosuppressive treatment for non-myeloid cancers. For patients with non-myeloid malignancies, chemotherapy and other anti-cancer medicines can often result in neutropenia, a condition involving an abnormally low number of neutrophils––a type of white blood cell––which increases the chance of life-threatening infectio...
Continue reading

Cancer Immunotherapy Collaborative Learning With Latha Shivakumar, PhD, CHCP

​In the constantly evolving field of cancer immunotherapy, it is crucial that community practitioners keep abreast of the latest advances. In this interview with i3 Health, Latha Shivakumar, PhD, CHCP, discusses her poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting concerning the initiative she led at the Association of Community Cancer Centers (ACCC): collaborative learning workshops focused on best practices for immunotherapy in the community setting. What ...
Continue reading

Copyright © 2021 Oncology Data Advisor. All rights reserved.